REG - Intelligent Ultrasnd - Directorate Change

Intelligent UltrasoundAnnouncement

26/05/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230526:nRSZ7287Aa&default-theme=true

RNS Number : 7287A  Intelligent Ultrasound Group PLC  26 May 2023

Intelligent Ultrasound Group plc

(the "Group" or the "Company")

 

Directorate Change

 

Intelligent Ultrasound Group plc (AIM: IUG), the 'classroom to clinic'
ultrasound company, specialising in artificial intelligence (AI) software and
simulation, announces that Ian Whittaker, who has served as an Executive
Director and Chief Operating Officer (COO) since joining the Group on the
acquisition of Inventive Medical Ltd in August 2016, will not be seeking
re-election to the Board of Directors at the 2023 Annual General Meeting
(AGM). Ian has also announced his intention to retire from his position as COO
on 31 December 2023 but will remain with the Group in a part time capacity to
assist on projects, as required.

 

The Board extends its thanks to Ian for his commitment and invaluable
contribution to significantly growing the simulation revenue and profitability
over the last seven years and wishes him continued success in his business and
personal endeavours.

 

For further information, please contact:

 

 Intelligent Ultrasound Group plc                www. intelligentultrasound.com
 Stuart Gall, CEO                                Tel: +44 (0)29 2075 6534
 Helen Jones, CFO

 Cenkos Securities - Nominated Advisor and Broker                Tel:  +44 (0)20 7397 8900
 Giles Balleny / Max Gould (Corporate Finance)
 Michael Johnson / Julian Morse (Sales)

 Walbrook PR     Tel: +44 (0)20 7933 8780 or intelligentultrasound@walbrookpr.com
 Anna Dunphy                     Mob: +44 (0)7876 741 001

 

 

ABOUT INTELLIGENT ULTRASOUND GROUP

 

Intelligent Ultrasound (AIM: IUG) is one of the world's leading 'classroom to
clinic' ultrasound companies, specialising in real-time hi-fidelity virtual
reality simulation for the ultrasound training market ('classroom') and
artificial intelligence-based clinical image analysis software tools for the
diagnostic medical ultrasound market ('clinic'). Based in Cardiff in
the UK and Atlanta in the US, the Group has two revenue streams:

 

Simulation

 

Real-time hi-fidelity ultrasound education and training through simulation.
Our main products are the ScanTrainer obstetrics and gynaecology training
simulator, the HeartWorks echocardiography training simulator,
the BodyWorks Eve Point of Care and Emergency Medicine training simulator
with Covid-19 module and the new BabyWorks Neonate and Paediatric training
simulator. To date over 1,450 simulators have been sold to over 700 medical
institutions around the world.

 

Clinical AI software

 

Deep learning-based algorithms to make ultrasound machines smarter and more
accessible using our proprietary ScanNav ultrasound image analysis technology.
Current products on the market utilising this technology are GE
Healthcare's SonoLyst software that is incorporated in their Voluson Expert
22 and SWIFT ultrasound machines; ScanNav Anatomy PNB that simplifies
ultrasound image interpretation by providing the user with real-time AI-based
anatomy highlighting for a range of ultrasound guided regional anesthesia
procedures; and NeedleTrainer that teaches real-time ultrasound-guided
needling and incorporates ScanNav Anatomy PNB.

 

www.intelligentultrasound.com (http://www.intelligentultrasound.com/)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAPPUQUAUPWGMA